Terms: = Ovarian cancer AND HER1, YOR227W
31 results:
1. Comparative anti-proliferative effects of potential HER2 inhibitors on a panel of breast cancer cell lines.
Zalloum H; AbuThiab T; Hameduh T; AlBayyari S; Zalloum W; Abu-Irmaileh B; Mubarak MS; Zihlif M
Breast Cancer; 2020 Mar; 27(2):213-224. PubMed ID: 31559601
[TBL] [Abstract] [Full Text] [Related]
2. NRF2 Regulates her1 Signaling Pathway to Modulate the Sensitivity of ovarian cancer Cells to Lapatinib and Erlotinib.
Kankia IH; Khalil HS; Langdon SP; Moult PR; Bown JL; Deeni YY
Oxid Med Cell Longev; 2017; 2017():1864578. PubMed ID: 29410730
[TBL] [Abstract] [Full Text] [Related]
3. ErbB Receptors and cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract] [Full Text] [Related]
4. Targeting peptidyl-prolyl isomerase pin1 to inhibit tumor cell aggressiveness.
Beretta GL; De Cesare M; Albano L; Magnifico A; Carenini N; Corna E; Perego P; Gatti L
Tumori; 2016; 102(2):144-9. PubMed ID: 26917410
[TBL] [Abstract] [Full Text] [Related]
5. An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Wang Z; Fu S
Expert Opin Investig Drugs; 2016; 25(1):15-30. PubMed ID: 26560712
[TBL] [Abstract] [Full Text] [Related]
6. Evaluation of the dimerization profiles of HER tyrosine kinases by time-resolved Förster resonance energy transfer (TR-FRET).
Lopez-Crapez E; Ho-Pun-Cheung A; Garnero P; Bazin H
Methods Mol Biol; 2015; 1233():45-55. PubMed ID: 25319888
[TBL] [Abstract] [Full Text] [Related]
7. The use of fluorescent proteins for developing cancer-specific target imaging probes.
McCann TE; Kosaka N; Choyke PL; Kobayashi H
Methods Mol Biol; 2012; 872():191-204. PubMed ID: 22700412
[TBL] [Abstract] [Full Text] [Related]
8. Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.
Albini A; Cesana E; Donatelli F; Cammarota R; Bucci EO; Baravelli M; Anzà C; Noonan DM
Future Cardiol; 2011 Sep; 7(5):693-704. PubMed ID: 21929348
[TBL] [Abstract] [Full Text] [Related]
9. Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: synthesis and biological evaluation.
Pisaneschi F; Nguyen QD; Shamsaei E; Glaser M; Robins E; Kaliszczak M; Smith G; Spivey AC; Aboagye EO
Bioorg Med Chem; 2010 Sep; 18(18):6634-45. PubMed ID: 20797871
[TBL] [Abstract] [Full Text] [Related]
10. PET imaging of her1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
Nayak TK; Regino CA; Wong KJ; Milenic DE; Garmestani K; Baidoo KE; Szajek LP; Brechbiel MW
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1368-76. PubMed ID: 20155263
[TBL] [Abstract] [Full Text] [Related]
11. Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer.
Baron AT; Wilken JA; Haggstrom DE; Goodrich ST; Maihle NJ
IDrugs; 2009 May; 12(5):302-8. PubMed ID: 19431095
[TBL] [Abstract] [Full Text] [Related]
12. Status of her1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma.
Uzan C; Darai E; Valent A; Graesslin O; Cortez A; Rouzier R; Vielh P
Virchows Arch; 2009 May; 454(5):525-9. PubMed ID: 19294416
[TBL] [Abstract] [Full Text] [Related]
13. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
Haluska P; Carboni JM; TenEyck C; Attar RM; Hou X; Yu C; Sagar M; Wong TW; Gottardis MM; Erlichman C
Mol Cancer Ther; 2008 Sep; 7(9):2589-98. PubMed ID: 18765823
[TBL] [Abstract] [Full Text] [Related]
14. Protein levels and gene expressions of the epidermal growth factor receptors, her1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
Steffensen KD; Waldstrøm M; Andersen RF; Olsen DA; Jeppesen U; Knudsen HJ; Brandslund I; Jakobsen A
Int J Oncol; 2008 Jul; 33(1):195-204. PubMed ID: 18575766
[TBL] [Abstract] [Full Text] [Related]
15. Treatment of premenopausal women with early breast cancer: old challenges and new opportunities.
Aebi S; Pagani O
Drugs; 2007; 67(10):1393-401. PubMed ID: 17600388
[TBL] [Abstract] [Full Text] [Related]
16. [Molecular diagnostic and targeted therapy--"Barking dogs are going to bite": presentations from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta 2006].
Rody A; Loibl S; Kaufmann M
Zentralbl Gynakol; 2006 Oct; 128(5):233-41. PubMed ID: 17001557
[TBL] [Abstract] [Full Text] [Related]
17. Expression of the epidermal growth factor system in endometrioid endometrial cancer.
Ejskjaer K; Sørensen BS; Poulsen SS; Forman A; Nexø E; Mogensen O
Gynecol Oncol; 2007 Jan; 104(1):158-67. PubMed ID: 16962163
[TBL] [Abstract] [Full Text] [Related]
18. ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study.
Leibl S; Bodo K; Gogg-Kammerer M; Hrzenjak A; Petru E; Winter R; Denk H; Moinfar F
Gynecol Oncol; 2006 Apr; 101(1):18-23. PubMed ID: 16330088
[TBL] [Abstract] [Full Text] [Related]
19. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (her1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study.
Gordon AN; Finkler N; Edwards RP; Garcia AA; Crozier M; Irwin DH; Barrett E
Int J Gynecol Cancer; 2005; 15(5):785-92. PubMed ID: 16174225
[TBL] [Abstract] [Full Text] [Related]
20. Emerging drugs for ovarian cancer.
Kelland LR
Expert Opin Emerg Drugs; 2005 May; 10(2):413-24. PubMed ID: 15934876
[TBL] [Abstract] [Full Text] [Related]
[Next]
